Samsung Biologics vs. Celltrion: Which Company Excels in Both Earnings and Employee Benefits?

[Korea Financial Times, Yang Hyunwoo] Samsung Biologics and Celltrion showed a gap in both first-half performance and employee benefits this year. Samsung Biologics outpaced Celltrion not only in revenue but also in areas such as parental leave usage.

According to a disclosure on the 18th, Samsung Biologics’ consolidated revenue for the first half of this year came in at KRW 2.5882 trillion, up 23% from the same period a year earlier. It set another half-year record high, following last year. Operating profit rose 47% to KRW 962.3 billion over the period, with an operating margin of 37%.

Excluding its subsidiary Samsung Bioepis, the contract development and manufacturing (CDMO) business also posted record revenue. On a standalone basis, Samsung Biologics recorded revenue of KRW 2.0138 trillion, up 36%, and operating profit of KRW 907.1 billion, up 61%.
A Samsung Biologics official said, “Improved operational efficiency at Plants 1–3 and the ramp-up of the 240,000-liter Plant 4 underpinned the strong results.” The company’s total production capacity stands at 784,000 liters, one of the highest in the world. It is currently proceeding with permits and groundwork to break ground on Plant 6.

After bringing the 180,000-liter Plant 5 online last year in April, the company plans to add three more plants by 2032, targeting total production capacity of 1,324,000 liters. Buoyed by the robust performance, the company raised its full-year consolidated revenue growth guidance by 5 percentage points to 25–30%.


During the same period, Celltrion reported revenue of KRW 1.8034 trillion and operating profit of KRW 391.9 billion, up 12% and 346% year-on-year, respectively. Its operating margin was 22%. A Celltrion official said, “Stable sales of existing products in global markets and expanded sales of high-margin new products drove the earnings growth.”

Celltrion’s first-half operating profit fell from KRW 365.4 billion in 2023 to KRW 87.9 billion last year before rebounding to KRW 391.9 billion this year. By contrast, Samsung Biologics’ figures have steadily increased—KRW 445.2 billion in 2023, KRW 655.8 billion in 2024, and KRW 962.3 billion in 2025.
The companies also diverged in cash generation. Samsung Biologics’ cash flow from operating activities in the first half of 2025 was KRW 1.2063 trillion, up KRW 677.0 billion from last year. This reflects a sharp increase in cash generated from operations to KRW 1.5719 trillion year-on-year.

Cash flow from investing activities was negative KRW 790.5 billion, widening from KRW 267.9 billion last year due to increased spending on buildings and equipment. Cash flow from financing activities was negative KRW 72.4 billion, a smaller net outflow than last year’s KRW 234.7 billion, reflecting reduced short-term borrowings and repayments.

Celltrion’s cash flow from operating activities was KRW 301.5 billion, down KRW 29.0 billion from last year. While cash generated from operations increased by KRW 124.1 billion to KRW 514.0 billion, corporate tax payments rose by KRW 153.1 billion, resulting in cash outflows.

Cash flow from investing activities was negative KRW 170.3 billion, swinging to a net outflow from KRW 68.5 billion last year. Cash flow from financing activities was negative KRW 439.8 billion, with the net outflow widening from negative KRW 76.1 billion last year due to increases in short- and long-term financial liabilities.

Differences were also notable in employee benefits. Samsung Biologics’ parental leave usage rate was 34%, ahead of Celltrion’s 9%. Adjusted for total headcount, Samsung Biologics also ranked higher: 2.64% for Samsung Biologics (5,047 employees) versus 1.79% for Celltrion (2,680 employees).

The retention rate of employees who returned from leave and remained for at least 12 months was 60% at Samsung Biologics and 57% at Celltrion, a modest gap. The number of employees taking spousal paternity leave was 79 at Samsung Biologics and 33 at Celltrion, translating into 1.57% and 1.23% of total headcount, respectively, with Samsung Biologics again higher.

An industry official said, “A balanced management strategy that encompasses not only profit generation but also cash flows and employee welfare appears to be the key to sustainable corporate growth.”

Yang Hyunwoo (yhw@fntimes.com)